So lets look at this another way. If MSLP does get Fuse for $700K in Jan but they take on the great drop products, patents(pending), athletes for advertising, how fast can I make up my loses from FUSE???

$30K in loses but I already own 8K shares of MSLP. I would suspect the loses can be made up in $4pps. With MSLP distribution and marketing this could be a no brainer and fast forward to $200M in sales in 1 year or less. This could be great, if your in MSLP.

I think this is the play.

Do you really think this is Brad's doing. None of this get completed without Frost. Frost owns 25% of MSLP and 25% of BZNE. He is controlling Brad, not the other way around. The biggest play here is getting costs under control ( control manufacturing ), bring new products to the table ( Arnold, fitmiss, qsomes ?? , transdermal patch )ect. revenues up to $200M runrate, and this stock goes sky high. The money that was lost on bzne today will be made up in spades with mslp.

Again, see you at $50 in 2 years or less. Sold off to who? Coke? Pepsi? Herbalife?

3 years from now we are sold for $50 - $75 pps. This is huge. And mslp will be very profitable. Stick with frost. Remember, he owns 25% of bzne.

Are we sure this is good news? Remember they just did this a few days ago.


Form 8-K for BIOZONE PHARMACEUTICALS, INC.

--------------------------------------------------------------------------------

31-Oct-2013

Unregistered Sale of Equity Securities, Amendments to Articles of I



Item 3.02. Unregistered Sales of Equity Securities.
On October 25, 2013, Biozone Pharmaceuticals, Inc. (the "Company") closed on the sale of 3,500 shares of Series A Preferred Stock ("Series A") in a private placement offering to 22 accredited investors for total gross proceeds of $3,500,000. The Series A investors also were issued 7,000,000 10-year warrants exercisable at $0.50 per share (the "Warrants"). The Series A: (i) have a stated value of $1,000, (ii) are convertible at $0.50 per share (the "Conversion Price") or a total of 7,000,000 shares of common stock and (iii) provide for 10% dividends per annum payable quarterly on March 31, June 30, September 30, and December 31, beginning on June 30, 2014 and on each conversion date. In lieu of a cash dividend payment, the Company may elect to pay all or part of a dividend in shares of common stock based on a conversion price equal to the lesser of:
(i) the Conversion Price and (ii) the average of the volume weighted average prices for the 20 consecutive trading days ending on the trading day that is immediately prior to the dividend payment date. The Company's right to pay a dividend in common stock is subject to the Company meeting certain equity conditions. The holders of Series A: (i) will vote together with the holders of common stock on an as converted basis and (ii) have a liquidation preference over the holders of the Company's common stock. The net proceeds to the Company were $3,410,000.

The Series A and Warrants sold have not been registered under the Securities Act of 1933 (the "Act") and were issued and sold in reliance upon the exemption from registration contained in Section 4(a)(2) of the Act and Rule 506(b) promulgated thereunder.

A form of Securities Purchase Agreement and Warrant are filed as exhibits under Item 9.01 and are incorporated herein by reference. The description of the offering described under this Item 1.01 is qualified in its entirety by reference to the full text of the Securities Purchase Agreement and Warrant, which are filed as Exhibits 10.1 and 10.2 to this Form 8-K.





Item 5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.
In connection with the offering, the Company filed a Certificate of Designation to its Articles of Incorporation designating 3,500 shares of its preferred stock. The description of the shares authorized under the Certificate of Designation set forth under Item 3.02 is incorporated into this Item 5.03 and is qualified in its entirety by reference to the full text of the Certificate of Designation, which is filed as Exhibit 3.1 to this Form 8-K.

So why would bzne do this below if they were getting bought out by mslp. This is preferred stock. I hope us little guys in bzne are not getting screwed.



Form 8-K for BIOZONE PHARMACEUTICALS, INC.

--------------------------------------------------------------------------------

31-Oct-2013

Unregistered Sale of Equity Securities, Amendments to Articles of I



Item 3.02. Unregistered Sales of Equity Securities.
On October 25, 2013, Biozone Pharmaceuticals, Inc. (the "Company") closed on the sale of 3,500 shares of Series A Preferred Stock ("Series A") in a private placement offering to 22 accredited investors for total gross proceeds of $3,500,000. The Series A investors also were issued 7,000,000 10-year warrants exercisable at $0.50 per share (the "Warrants"). The Series A: (i) have a stated value of $1,000, (ii) are convertible at $0.50 per share (the "Conversion Price") or a total of 7,000,000 shares of common stock and (iii) provide for 10% dividends per annum payable quarterly on March 31, June 30, September 30, and December 31, beginning on June 30, 2014 and on each conversion date. In lieu of a cash dividend payment, the Company may elect to pay all or part of a dividend in shares of common stock based on a conversion price equal to the lesser of:
(i) the Conversion Price and (ii) the average of the volume weighted average prices for the 20 consecutive trading days ending on the trading day that is immediately prior to the dividend payment date. The Company's right to pay a dividend in common stock is subject to the Company meeting certain equity conditions. The holders of Series A: (i) will vote together with the holders of common stock on an as converted basis and (ii) have a liquidation preference over the holders of the Company's common stock. The net proceeds to the Company were $3,410,000.

The Series A and Warrants sold have not been registered under the Securities Act of 1933 (the "Act") and were issued and sold in reliance upon the exemption from registration contained in Section 4(a)(2) of the Act and Rule 506(b) promulgated thereunder.

A form of Securities Purchase Agreement and Warrant are filed as exhibits under Item 9.01 and are incorporated herein by reference. The description of the offering described under this Item 1.01 is qualified in its entirety by reference to the full text of the Securities Purchase Agreement and Warrant, which are filed as Exhibits 10.1 and 10.2 to this Form 8-K.





Item 5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.
In connection with the offering, the Company filed a Certificate of Designation to its Articles of Incorporation designating 3,500 shares of its preferred stock. The description of the shares authorized under the Certificate of Designation set forth under Item 3.02 is incorporated into this Item 5.03 and is qualified in its entirety by reference to the full text of the Certificate of Designation, which is filed as Exhibit 3.1 to this Form 8-K.

Maybe the rest of the company which has the pharma side goes to opko. Mslp get the manufacturing and qsomes delivery and opko get the rest. Not sure what happens to the bzne share price.

Not sure what this means to bzne which I have a few shares of as well.. It doesn't look like they are left with much after this and yahoo says it only has 354K in cash and 6M in debt.

It's out on yahoo now.

On November 12, 2013, Biozone Pharmaceuticals, Inc. (the “Company”), Biozone Laboratories, Inc. (“Bio Lab”), Baker Cummins Corp. (“BCC”) (the Company, Bio Lab and BCC are collectively referred to as “Biozone”), Brian Keller, MusclePharm Corporation (“Musclepharm”) and Biozone Laboratories, Inc. (“Acquisition Co.”), a newly formed subsidiary of Musclepharm, entered into an Asset Purchase Agreement (the “Agreement”). The Agreement provides that Acquisition Co. will acquire substantially all of the operating assets of Biozone including the QuSomes, HyperSorb and EquaSomes drug delivery technologies (excluding certain assets including cash on hand) for 1,200,000 shares of Musclepharm’s common stock. Of the 1,200,000 shares being issued under the Agreement, (i) 600,000 of the shares will be issued to the Company upon closing and (ii) 600,000 of the shares (the “Escrowed Shares”) will be placed in escrow for nine months from the date of closing (the “Escrow Period”). During the Escrow Period, Musclepharm will have the option to purchase the Escrowed Shares at $10.00 per share in cash. The Escrowed Shares will also back-stop potential indemnification claims that Acquisition Co. may have under the Agreement.

MSLP buys BZNE. BIG NEWS..

Dr. Frost at work. This is huge for both companies.

Yes but the difference is mslp will have over 100m in rev , no debt and a huge market in front of it. fuse will do the same with the guidance of dr. frost and others. sometimes rev splits do well.

Tontis and Bgrass are one in the same.

This is plain and simple a bridge loan. DROP expects huge sales numbers coming in the next several months and they needed the $$ to replenish the shelves. Frost, MSLP and BZNE are all connected and DROP will finally make good on its promise to be a major player in this market. At some point in time DROP/MSLP/BZNE may all be one company sold to a much larger entity. No not OPKO but maybe coke with the piece of bzne that affects opk sold off to them. This is a huge tri fecta in the making. Buy all three and look at them 2-3 years from now.

Gentleman, this is all about Dr. Phillip Frost. He is the CEO of OPK who has a large stake in MSLP. He owns about 25% of them. He also is a large owner in BZNE which MSLP has a vested interest in along with a manufacturing agreement with. I would not be surprised if FUSE will be doing their manufacturing with BZNE. Both BZNE and MSLP are heading north. MLSP will be a $20 stock by March. BZNE will be a $5 stock by the end of next year. If you look into Dr. Frost ( BTW, ex Chairman and CEO of TEVA pharm ) you will find a web of companies all tied together. Go to the OPKO web site and find the Jefferies Conf. presentation. You will see most of the info there but it is a bit dated. OPK will be a $25 stock by the end of next year, if not higher. We will now see the true value of DROP move forward in quick fashion. This could be a .50c stock by mid next year.

anyone know what is up with the MP web site? Basically down except for a product list with link to buy.

JLTG, see the news out after hours. Drew C. is gone and MSLP has the rights to MP Sportswear. This is good news, no?

The hits just keep coming. $20 by March.

So lets see. If you do not believe what I am saying then you are a short. If you tell me you are long then why the massive amounts of negativity. Right now the sec investigation is for 2010 and 2011. Could they include 2012, of course but why haven't they already? So I take what the sec is looking at with a grain of salt. I don't really care what happened back in 2010/11. I care about now. If the sec issue puts additional constraints on brad/cory and the team that is great.

What I am looking at is a massive marketing plan that will get us into a $200M runrate by March if not sooner. That is huge. By then hopefully the sec issue is gone and we have a huge winner. I just hate all the negatives based on no real good info. Wait for next week when we hear about the quarter and going forward plan of attack. I believe it will be great. We probably will not hear a thing about sec but that will take time.

I see it just the opposite but I know that you like to stir the pot and try and avg down ( looking for cheap shares by causing controversy ) . But the upside is huge for mslp. If not why are you hear? Still licking your wounds from when this was a penny stock when you lost a ton of $$$. Get on the long side and you will see this rocket when the sec trouble is much ado about nothing and that the revenues blow away everyone's expectations. Train to $20 rolling down the tracks. Should be here by March or sooner.

Does anyone have any real info on the 4K release. Do we now have to wait for the validation testing to be performed or can we still do a formal product release to get this going? Info flow from the company is not good.

Yes, same question for me. Cannot find the sidoti report anywhere.
Thx.

what are you talking about?? and who put the bug up your butt?

Lets not forget the end game here. Getting to $200M in revenue or a $200M in rev run rate ( which is avg. $50M per qtr ) is the the key. We get there this will be sold off for 2.5x sales or $500M. That will translate into a pps of $55. That is why we are in this. Arnold will get you there and probably much quicker than 2 years out. $115 this year or run rate of $29M avg. 50% growth for next year or $172M. That is a $43M run rate. Then shop for sale of company. If we keep going without a sale, 25% growth the next year we are over $200M. Only 25% growth, it could be much more.

Sell this thing for 70-80 with $250 in sales. I can wait. Dr. Frost is in charge. BTW, Biozone will be in the $20 range at that time as well. Huge winners.

The $103M in rev sounds more like the corporate line from last quarters earnings call. They have been in that range for a while now. Maybe they are just taking it from what the company line has been. It should be closer to the $115-$125 range.

That is the issue. He came out of the blue and starts to bash the company without any facts. At least some of the guys who do the bashing here has some validity. This guy could have picked anything else to base, but he picks on product quality without one bit of fact to back himself up. Even after repeated requests for his insight as to why the prod quality is horrible. The guy is a hack.

$120M in sales, Arnold and Dr. Frost don't think the products are bad. Why do you breaking wind?

DS, what Greek bank are you in? I just loaded up on a ton of leaps for NBG. Going out 1 and 2 years. Looking for a huge recovery and a $20-$30 target price by 2016. This thing was $32 earlier this year. The options are cheap and if Greece recovers, this bank will take off very quickly like Citi and BOA did.

Did Dr. Frost just get in recently or did he get in with the CEO who just left? If he just got in that is great. If he was in 6 months ago I would be a bit nervous with this big hitter from Coke leaving after just a short time on board.

What makes that buy so great. It is a 10K purchase.

Just out on schwab: This will probably sell off a bit based on this. 5M preferred shares??

BZNE just put out an 8K

Item 5.03. Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.


On October 10, 2013, Biozone Pharmaceuticals, Inc. (“Biozone”) filed a Certificate of Amendment to its Articles of Incorporation to increase its authorized shares of common stock to 200,000,000 and authorize 5,000,000 shares of preferred stock. Prior to the amendment, Biozone was authorized to issue 100,000,000 shares of common stock and no shares of preferred stock.

Here is the wording on the 5% rule. See the last paragraph.

Form 5 filings are an annual summation of the Form 4 changes to give an annual summation of the ownership by officers, directors, and 10% owners.

For clarity, the Form 13D is a required filing by any entity that becomes a 5% holder. This filing must be made at the time (within 10 days) the holder crosses the 5% threshold. Form 13G is the same form, but used when the person or entity is making the purchase for "investment" only.) Additional purchases by this holder do not have to be reported on Forms 3, 4, or 5, until the holder crosses the 10% threshold.

Insiders who purchase or sell stock on the open market, just as any other investor, have to file these transactions on a Form 4 filing, but do not have list sales with a Form 144.

Just because half of his shares are restricted he still must file as a 5% owner.

Arnold is a 5% guy so he would have to file. He is not selling a dime.

How about this one major positive.

The news broke about the sec investigation , the stock dropped almost 3 points, then buyers stepped in. Someone thinks that the investigation has little bearing on the long term price of the stock.

This should be in limbo as the particulars are sorted out but if they can continue to sell and make this into $125M in rev this year and $200M next year the sec thing will go away. When it does it set the stage for a buyout in the $40 - $50 area. There are buyers at every dip.

They don't respond because they are positioning themselves as the company executives that they are. How many CEO's or VP's are responding to FB or Twitter? Very few although it is a practice that is increasing. Not to respond but to release info.

Well I appreciate the candor. I'm just hoping for .04c to dump.

You do not go into a uplifting if you think all your dirty secrets will be found out. Dr. Frost and Bluher are not Brad and Cory. This will not be as bad as we all think but we will test 8 again. There are no one day events when it comes to the sec.

How do you get from less than a penny to a dime. Just wondering what you think the drivers will be.

The are plenty of buyers at 9.70 - 9.75. The shares have been stuck there for a while now. I have been cutting back at this level to see what transpires over the next press release. I hope we get one that says Dr. Frost has stepped back in again and have purchased on the open market. I'm actually buying more opko with my mslp sales. I would gladly give up a point or two to see what this outcome will be and who takes the ball as our new CEO.

So who is buying all the shares today? Do we go positive for the day? I thought for sure we would be hanging in the $8 range all day waiting for some news.

Dr. Frost's OPK is taking off today.